270offulvestrantinmalebreastcancer,whereasonlylim-iteddataexistintheliteraturecomingfromcasereports/smallcaseserieswiththeuseofthisagentinmenwithbreastcancer.However,availableinvitrodataalongwiththemechanismofaction[5]indicatethatfulvestrantmayrepresentausefultreatmentoptionformalebreastcancerpatients.
Thisisthe rstpooledanalysisoftheliteraturetosyn-thesizeallavailabledataemergingfromcasereports/caseseriesandtoevaluatetheef cacyandsafetyoffulvestrantinmalebreastcancer.
Materialsandmethods
Selectionofstudiesanddataabstraction
ThispooledanalysiswasundertakenfollowingthePRISMAguidelines[8].Theprotocolofthispooledana-lysishasbeensubmittedtotheInstitutionalReviewBoardofAlexandraHospital,MedicalUniversityofAthens,Greeceandisavailableuponrequest.EligiblearticlesweresoughtinMEDLINE,uptoOctober15,2014.Thesearchstrategyincludedthefollowingalgorithm:breastAND(neoplasmsORneoplasmORcancerORcancersORcar-cinomaORcarcinomas))ANDfulvestrantAND(maleORmen).
Languagerestrictionswerenotapplied;twoinvestiga-tors(FZandDC),workingindependently,performedtheliteraturesearchandabstracteddatafromeligiblestudies.Reviewswerenoteligible,whileallprospectiveandret-rospectivestudies,aswellascasereports,wereconsideredeligible.Moreover,ina‘‘snowball’’procedure,weexam-inedallreferencesineligiblearticlesandinrelevantreviewsretrievedbyoursearch,identifyingpotentiallyeligibleconferenceabstracts.Casesoffulvestrantco-administrationwithotherhormonalagentswereexcludedfromthisanalysis.
Allstudiesexaminingtheef cacy(responseand/orsurvival)andsafety(adverseevents)offulvestrantinmalebreastcancerwereconsideredeligible,regardlessofsam-plesize.Evidently,studieswithfulvestrantadministrationinmalebreastcancerpatientswithoutreportinganydataregardingef cacyoradverseeventswereexcludedfromthisanalysis.Foreligiblestudies,thefollowingdatawerecollected: rstauthor,yearofpublication,doseoffulve-strantadministration,characteristicsofpatientpopulation(pathologicaltype,initialstage,grade,ER,PRandHER2status,ki-67),age(years),previoustreatments(hormonaltreatment,chemotherapy),lineoftreatment,response[completeresponse(CR),partialresponse(PR),stabiliza-tionofthedisease(SD),progressionofthedisease(PD)],typeofmetastases(visceral,bone)medianoverallsurvival
123
BreastCancerResTreat(2015)149:269–275
(OS)inmonths,medianprogression-freesurvival(PFS)inmonths,complications.Responseofdiseasewasde nedasstatedintheeligiblecasereports..
Regardingourpreviouspublicationonthetopic[9],additionaldatapertainingtotypeofmetastases(visceral,bone)andsideeffectswereprovidedforthispooledanalysis.
Quantitativesynthesisandstatistics
Regardingthequantitativesynthesis(pooledanalysis)ofthepublishedstudies,twosetsofcalculationswereper-formed.First,thedescriptivestatisticswerecalculated.Kaplan–MeiersurvivalcurveswereestimatedforPFS,forthegraphicalpresentationofresults.Second,factorspotentiallyassociatedwith(1)PFSand(2)clinicalbene t(PRandSDgroupedtogether,versusPD)wereevaluated;tothisend,univariateCoxregressionanalysesanduni-variatelogisticregressionanalyseswereperformed,respectively.Thepotentiallyprognosticfactorsthatwereevaluatedwerethefollowing:ageatfulvestrantadminis-tration,linesoftreatment,grade,initialstageatdiagnosis,HER2status,PRstatus,prioradjuvanthormonaltreatment,prioradjuvantchemotherapy,visceralmetastases,bonemetastases,hot ashes.Incaseofnotestimableoddsratios,duetothepresenceofazerocellinthecorresponding292table,thep-valueswerederivedfromFisher’sexacttest.
Thestatisticalanalysisshouldbedeemedexplorativegiventhesmallsamplesize,aswellasinlightofthequestionablecomparabilityofcasesamongthevariousstudies.StatisticalanalysiswasperformedwithSTATA/SE13statisticalsoftware(StataCorp,CollegeStation,TX,USA).
Results
Thesearchstrategyretrieved31articles.Ofthesearticles,19wereirrelevant,fourwerereviews,threewereexclu-dedduetovariousreasons[10–12](co-administrationoffulvestrantwithanotherhormonalagent[10],lackofdatapertainingtoef cacyorsafety[11,12])and vewereeligible[9,13–16].Aftersearchingthereferencesofallreviewsandremainingarticles,noadditionalconferenceabstracts/articleswereincluded.Overall, vestudies(23patients)wereeligibleforthispooledanalysis(Table1).TheaforementionedstepsareillustratedindetailinFig.1.
Themeanageofthestudysamplewas63.1years(SD:9.0,median64).Themajorityofpatients(86.7%)pre-sentedwithIDC,whereas13.3%presentedwithILC.Stageatinitialdiagnosiswasasfollows:stageI12.5%,II
(×200)?From?Zagouri?et? al?BMC?Cancer?2010 Hsp90?Expression?in?Breast?Cancers?by?protein? expression?analysis?(AQUA)?From?Pick?et?al?Cancer? ...
Greece? (Zagouri? F);? and? Department?of?Surgery,?Red?Cross?Hospital,?Athens,?Greece?(Karaliotas?K) Corresponding? Author:? Flora? Zagouri,? MD,? ...
A Case Study of an in Situ Botanical Garden in Zagori, Greece_电子/电路_工程科技_专业资料。Journal ofAgricultural Science and Technology B 3(2 ...
热门文档